Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brequinar

Next Previous
Drug Profile

Brequinar

Alternative Names: Bipenquinate; Brequinar sodium; DUP 785; NSC 368390; NSC 369390

Latest Information Update: 06 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Clear Creek Bio
  • Class Biphenyl compounds
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia
  • Discontinued Cancer; Cytomegalovirus infections; Transplant rejection

Most Recent Events

  • 26 Nov 2018 Phase-I/II clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (PO) (NCT03760666)
  • 01 Oct 2018 The US FDA approves IND application for brequinar in acute myeloid leukaemia (Clear Creek Bio website, December 2018)
  • 18 Dec 1998 A study has been added to the Transplant rejection pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top